Basic Information
| LncRNA/CircRNA Name | MIR22HG |
| Synonyms | NA |
| Region | GRCh38_17:1711493-1717174 |
| Ensemble | ENSG00000186594 |
| Refseq | NR_028502 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | colorectal cancer |
| ICD-0-3 | C19.9 |
| Methods | qRT-PCR, Western blot |
| Sample | CRC tissues,cell lines |
| Expression Pattern | down-regulated |
| Function Description | MIR22HG exerts its tumor suppressive activity by competitively interacting with SMAD2 and modulating the activity of TGF? pathway. Decreased MIR22HG promoted the epithelial-mesenchymal transition in CRC.MIR22HG expression is significantly correlated with CD8A and overexpression of MIR22HG triggers T cell infiltration, enhancing the clinical benefits of immunotherapy. |
| Pubmed ID | 32127004 |
| Year | 2020 |
| Title | MIR22HG acts as a tumor suppressor via TGF?/SMAD signaling and facilitates immunotherapy in colorectal cancer |
External Links
| Links for MIR22HG | GenBank HGNC NONCODE |
| Links for colorectal cancer | OMIM COSMIC |